British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA 1/2 variants in ovarian cancer in the United Kingdom

Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19.

Abstract

The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.

Keywords: BRCA1 protein; BRCA2 protein; fallopian tube neoplasms; ovarian neoplasms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • BRCA1 Protein*
  • BRCA2 Protein*
  • Carcinoma, Ovarian Epithelial / genetics*
  • Consensus
  • Female
  • Genetic Predisposition to Disease
  • Genetic Testing / standards
  • Germ-Line Mutation
  • Humans
  • Ovarian Neoplasms / genetics*
  • United Kingdom

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human